145 related articles for article (PubMed ID: 12005203)
21. The dual inhibitor of lipoxygenase and cyclooxygenase ML3000 decreases the expression of CXCR3 ligands.
Ospelt C; Kurowska-Stolarska M; Neidhart M; Michel BA; Gay RE; Laufer S; Gay S
Ann Rheum Dis; 2008 Apr; 67(4):524-9. PubMed ID: 17666446
[TBL] [Abstract][Full Text] [Related]
22. Influence of nonsteroidal anti-inflammatory drugs on the antiplatelet effects of aspirin in rats.
Akagi Y; Nio Y; Shimada S; Aoyama T
Biol Pharm Bull; 2011; 34(2):233-7. PubMed ID: 21415533
[TBL] [Abstract][Full Text] [Related]
23. Effect of vintoperol on platelet aggregation and experimental thrombosis.
Csomor K; Kárpáti E
Arzneimittelforschung; 1994 Jan; 44(1):36-40. PubMed ID: 8135876
[TBL] [Abstract][Full Text] [Related]
24. Antithrombotic effects of Huanglian Jiedu decoction in a rat model of ischaemia-reperfusion-induced cerebral stroke.
Liu H; Chen X; Liu Y; Fang C; Chen S
Pharm Biol; 2021 Dec; 59(1):823-827. PubMed ID: 34196572
[TBL] [Abstract][Full Text] [Related]
25. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
Azzam K; Cissé-Thiam M; Drouet L
Thromb Haemost; 1996 Jan; 75(1):203-10. PubMed ID: 8713802
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
Nagakura N; Saeki T; Harada K; Yoshitake S; Kobayashi S; Yamanaka T; Saito I
Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481
[TBL] [Abstract][Full Text] [Related]
27. Augmentation of U46619 induced human platelet aggregation by aspirin.
Kim JM; Koo YK; Jin J; Lee YY; Park S; Yun-Choi HS
Platelets; 2009 Mar; 20(2):111-9. PubMed ID: 19235053
[TBL] [Abstract][Full Text] [Related]
28. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
[TBL] [Abstract][Full Text] [Related]
29. Total steroidal alkaloids from Veratrum patulum L. Inhibit platelet aggregation, thrombi formation and decrease bleeding time in rats.
Song Q; Wang S; Zhao W
J Ethnopharmacol; 2012 May; 141(1):183-6. PubMed ID: 22366682
[TBL] [Abstract][Full Text] [Related]
30. Additive antithrombotic effect of ASP6537, a selective cyclooxygenase (COX)-1 inhibitor, in combination with clopidogrel in guinea pigs.
Sakata C; Suzuki KI; Morita Y; Kawasaki T
Eur J Pharmacol; 2017 Mar; 798():72-76. PubMed ID: 28095326
[TBL] [Abstract][Full Text] [Related]
31. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
[TBL] [Abstract][Full Text] [Related]
32. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative.
Wallace JL; McKnight W; Del Soldato P; Baydoun AR; Cirino G
J Clin Invest; 1995 Dec; 96(6):2711-8. PubMed ID: 8675638
[TBL] [Abstract][Full Text] [Related]
33. Antiplatelet and antithrombotic activities of Korean Red Ginseng.
Yu JY; Jin YR; Lee JJ; Chung JH; Noh JY; You SH; Kim KN; Im JH; Lee JH; Seo JM; Han HJ; Lim Y; Park ES; Kim TJ; Shin KS; Wee JJ; Park JD; Yun YP
Arch Pharm Res; 2006 Oct; 29(10):898-903. PubMed ID: 17121186
[TBL] [Abstract][Full Text] [Related]
34. Antithrombotic activity of methanolic extract of Umbilicaria esculenta.
Kim MS; Lee KA
J Ethnopharmacol; 2006 May; 105(3):342-5. PubMed ID: 16384677
[TBL] [Abstract][Full Text] [Related]
35. Hydroxychavicol, a novel betel leaf component, inhibits platelet aggregation by suppression of cyclooxygenase, thromboxane production and calcium mobilization.
Chang MC; Uang BJ; Tsai CY; Wu HL; Lin BR; Lee CS; Chen YJ; Chang CH; Tsai YL; Kao CJ; Jeng JH
Br J Pharmacol; 2007 Sep; 152(1):73-82. PubMed ID: 17641677
[TBL] [Abstract][Full Text] [Related]
36. Antithrombotic and antiplatelet activities of 2-chloro-3-[4-(ethylcarboxy)-phenyl]-amino-1,4-naphthoquinone (NQ12), a newly synthesized 1,4-naphthoquinone derivative.
Yuk DY; Ryu CK; Hong JT; Chung KH; Kang WS; Kim Y; Yoo HS; Lee MK; Lee CK; Yun YP
Biochem Pharmacol; 2000 Oct; 60(7):1001-8. PubMed ID: 10974210
[TBL] [Abstract][Full Text] [Related]
37. Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors.
Kobzar G; Mardla V; Samel N
Platelets; 2011; 22(5):338-44. PubMed ID: 21557683
[TBL] [Abstract][Full Text] [Related]
38. Antithrombotic activity of Z4A5, a new platelet glycoprotein IIb/IIIa receptor antagonist evaluated in a rabbit arteriovenous shunt thrombosis model.
Jing BB; Li YX; Zhang H; Ren ST; Wang M; Li YP; Zang WJ; Wang B
Thromb Res; 2011 Nov; 128(5):463-9. PubMed ID: 21924458
[TBL] [Abstract][Full Text] [Related]
39. ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury.
Wallace JL; Carter L; McKnight W; Tries S; Laufer S
Eur J Pharmacol; 1994 Dec; 271(2-3):525-31. PubMed ID: 7705453
[TBL] [Abstract][Full Text] [Related]
40. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit.
Herbert JM; Dol F; Bernat A; Falotico R; Lalé A; Savi P
Thromb Haemost; 1998 Sep; 80(3):512-8. PubMed ID: 9759636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
